Every lab has that one reagent that sat in the back of the freezer, the third-generation backup nobody had high hopes for. Lorlatinib started its career a little like that - the late-arriving ALK inhibitor in a crowded field, the one designed mostly to mop up after its predecessors failed. Seven years into the CROWN study, that scrappy backup is the only one still standing, and it's not even breathing hard.
What CROWN Actually Did
Here's the setup. Researchers took 296 people with advanced ALK-positive non-small cell lung cancer - a subtype driven by a busted ALK gene that acts like a stuck accelerator pedal in the cell - and flipped a coin. Half got crizotinib, the old reliable first-line drug. Half got lorlatinib. Then everyone waited. For seven years. (If you've ever babysat a long-term experiment, you know that "median follow-up of 83 months" is a polite way of saying several scientists' entire PhD timelines.)
The headline number is almost rude. Median progression-free survival - the time before the cancer starts growing again - was 9.1 months for crizotinib. For lorlatinib, the median is still not reached. Seven years in, they cannot calculate the halfway point because more than half the patients haven't progressed. At the 7-year mark, 55% of the lorlatinib group was still cruising along without progression. The crizotinib group? Three percent.
Let me put that in bench terms: if crizotinib is a Western blot that gives you a clean band for a few months before the signal fades, lorlatinib is the one inexplicably still glowing when you walk back into the darkroom seven years later, and you're a little suspicious that someone swapped your film.
The Brain Is Where It Gets Wild
ALK-positive lung cancer has a nasty habit of spreading to the brain, which historically has been the part that ends the conversation. Lorlatinib was built to cross into the brain, and the data show it. Time to intracranial progression for crizotinib was 16.4 months. For lorlatinib, again, not reached - with a hazard ratio of 0.06, which is statistician-speak for "these two things are barely in the same universe."
The part that made me reread the abstract twice: no new brain progression events happened after the first 30 months on lorlatinib. If you cleared the two-and-a-half-year mark with your brain quiet, it apparently stayed quiet. That's not how cancer is supposed to behave, and I mean that as the highest compliment.
The "If You Make It to Year Two" Rule
Buried in the results is something genuinely useful for patients and clinicians. Among people on lorlatinib who had no progression at the 24-month mark, there was a 79% chance they'd still be progression-free at year seven. Survive the first two years and the odds tilt hard in your favor. The drug also stopped being a discontinuation problem early - no treatment-related side effects forced anyone off lorlatinib after the first 26 months. The bodies adjusted, and then things settled.
The ctDNA Detective Work
Because no result is allowed to be purely clean, the team did the thing every bench scientist secretly loves: they went digging for why some people progressed early anyway. Sifting circulating tumor DNA - the genetic confetti tumors shed into the blood - they found that early progressors carried more genetic alterations than the long-term responders, and they flagged new potential resistance mechanisms. Translation: the tumors that escaped did it by stacking extra mutations, and now we have leads on what to watch for next. That's the part that keeps the field employed.
Why This Matters
Overall survival data isn't mature yet - not enough events have occurred to run the protocol-specified analysis, which is its own kind of good news. But the authors say something that would have sounded delusional a decade ago: first-line lorlatinib may be turning advanced ALK-positive lung cancer into something closer to a chronic condition you manage, rather than a sprint you lose.
For a disease that used to be measured in months, "we can't find the median after seven years" is the kind of result you double-check, then triple-check, then quietly believe.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.
References
-
Shaw AT, Solomon BJ, Felip E, et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study. Annals of Oncology. 2026. DOI: 10.1016/j.annonc.2026.05.692. PMID: 42217582.
-
Solomon BJ, Liu G, Felip E, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of Clinical Oncology. 2024. DOI: 10.1200/JCO.24.00581.
-
Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383:2018-2029. DOI: 10.1056/NEJMoa2027187.
-
Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nature Reviews Cancer. 2013;13:685-700. DOI: 10.1038/nrc3580.